Review article · 2017
EditorialPublished 2015
Drug Review Differences across the United States and the European Union
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Mikaela M Sifuentes and Andrea Giuffrida PDF Share this article
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 26 Oct 2015
Comparison of regulatory requirements for marketing authorization of biologics in United States and European Union
Conference abstract · 25 Aug 2015
Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
Mini review · 15 Feb 2019
Bioequivalence Guidelines Requirements for Orally Administered Generics (IR Products) in Gulf Cooperation Council Countries, European Union and United States of America
Short communication · 14 Sep 2023
High Consistency between Regulatory Decisions for New Drugs between the Swiss Swissmedic, the European Medicines Agency and the United States Food and Drug Administration
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Mikaela M Sifuentes”
- BylineArticles whose byline prints “Andrea Giuffrida”

